CoChat

PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

Open access
Xu, Jian-Ming, Wang, Yan, Wang, You-Liang, Wang, Yan, Liu, Tao, Ni, Ming, Li, Man-Sheng, Lin, Li, Ge, Fei-Jiao, Gong, Chun, Gu, Jun-Yan, Jia, Ru, Wang, He-Fei, Chen, Yu-Ling, Liu, Rong-Rui, Zhao, Chuan-Hua, Tan, Zhao-Li, Jin, Yang, Zhu, Yun-Ping, Ogino, Shuji, Qian, Zhi-Rong · 2017 · Clinical Cancer Research
Cited by 76

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Purpose: Mutations in KRAS are considered to be the main drivers of acquired resistance to epidermal growth factor receptor (EGFR) blockade in patients with metastatic colorectal cancer (mCRC). However, the potential role of other genes downstream of the EGFR signaling pathway in conferring acquired resistance has not been extensively investigated. Experimental Design: Using circulating tumor DNA (ctDNA) from patients with mCRC and with acquired cetuximab resistance, we developed a targeted amplicon ultra-deep sequencing method to screen for low-abundance somatic mutations in a panel of genes that encode components of the EGFR signaling pathway. Mutations with significantly increased variant frequencies upon disease progression were selected by using quartile analysis. The functional consequences of the identified mutations were validated in cultured cells. Results: We analyzed 32 patients with acquired cetuximab resistance in a development cohort. Of them, seven (22%) carried five novel PIK3CA mutations, whereas eight (25%) carried previously reported KRAS mutations. Functional studies showed that novel PIK3CA mutations (all in exon 19; p.K944N, p.F930S, p.V955G, p.V955I, and p.K966E) promote cell viability in the presence of cetuximab. Only one novel PIK3CA mutation (p.K944N) was verified in one of the 27 patients with acquired resistance in a validation cohort, simultaneous KRAS and PIK3CA hotspot mutations were detected in two patients. Among the above 59 acquired resistance patients, those with PIK3CA or RAS mutations detected in ctDNA showed a pronounced decrease in progression-free survival than patients with no mutation. Conclusions: The PIK3CA mutations may potentially contribute to acquired cetuximab resistance in patients with mCRC. Clin Cancer Res; 23(16); 4602–16. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-2738

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 76

Metadata

Authors
Xu, J.-M., Wang, Y., Wang, Y.-L., Wang, Y., Liu, T., Ni, M., Li, M.-S., Lin, L., Ge, F.-J., Gong, C., Gu, J.-Y., Jia, R., Wang, H.-F., Chen, Y.-L., Liu, R.-R., Zhao, C.-H., Tan, Z.-L., Jin, Y., Zhu, Y.-P., Ogino, S., & Qian, Z.-R.
Venue
Clinical Cancer Research
Published
2017-08-14
Volume
23
Issue
16
Pages
4602-4616
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2606050648
Cited by
76
References
13
FWCI
3.66
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-2738
The paper
Xu, J.-M., Wang, Y., Wang, Y.-L., Wang, Y., Liu, T., Ni, M., Li, M.-S., Lin, L., Ge, F.-J., Gong, C., Gu, J.-Y., Jia, R., Wang, H.-F., Chen, Y.-L., Liu, R.-R., Zhao, C.-H., Tan, Z.-L., Jin, Y., Zhu, Y.-P., . . . Qian, Z.-R. (2017). PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-2738

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.